Form 8-K - Current report:
SEC Accession No. 0001104659-25-004159
Filing Date
2025-01-16
Accepted
2025-01-16 17:16:07
Documents
19
Period of Report
2025-01-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm253522d1_8k.htm   iXBRL 8-K 55905
2 EXHIBIT 4.1 tm253522d1_ex4-1.htm EX-4.1 105216
3 EXHIBIT 4.2 tm253522d1_ex4-2.htm EX-4.2 105330
4 EXHIBIT 4.3 tm253522d1_ex4-3.htm EX-4.3 105266
5 EXHIBIT 4.4 tm253522d1_ex4-4.htm EX-4.4 105341
6 EXHIBIT 10.1 tm253522d1_ex10-1.htm EX-10.1 72094
7 EXHIBIT 10.2 tm253522d1_ex10-2.htm EX-10.2 79524
  Complete submission text file 0001104659-25-004159.txt   955693

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250116.xsd EX-101.SCH 3304
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250116_lab.xml EX-101.LAB 34750
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250116_pre.xml EX-101.PRE 22381
21 EXTRACTED XBRL INSTANCE DOCUMENT tm253522d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25536395
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)